[Self-evaluation of single test doses and objective indices of ladasten vs. placebo efficacy in neurasthenic patients].

Reutova MA, Siuniakov SA, Siuniakov TS, Dorofeeva OA, Mametova LÉ, Neznamov GG

Eksperimental'naia i klinicheskaia farmakologiia1 Jan 2011

PMID22288153PepBankPUB-22288153

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanNon-randomized trialSafety outcome
In patients with neurasthenia, self-rated tolerability of ladasten was high and comparable with placebo.
In plain wordsIn patients with neurasthenia, self-rated tolerability of ladasten was comparable with placebo.
Peptide
Bromantane
Outcome
No significant changeSelf-rated tolerability
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
15 mg · single doseAs given in this study (human).
Source sentences
Summary
Results suggest that the self-rated high tolerability of ladasten treatment is comparable with that of placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Self-evaluation of the effect of single-dose (15 mg) ladasten administration versus placebo has been studied in patients with neurasthenia diagnosis.
Report a problemFND-2228815301
02HumanNon-randomized trialOther
In patients with neurasthenia, self-rated single-dose ladasten effects had no relationship with personal features.
In plain wordsIn patients with neurasthenia, self-rated ladasten effects were not linked to personal features.
Peptide
Bromantane
Outcome
No significant changeAssociation of self-rated effects with personal features
Study
n: not reported in source
Outcome group
Patient-reported outcomes · Mental health and mood
Studied dose
15 mg · single doseAs given in this study (human).
Source sentences
Summary
No relationships are found between the self-evaluated single-dose effects of ladasten and personal features of patients.
1 context sentence(design, population, supporting numbers)
Summary · context
Self-evaluation of the effect of single-dose (15 mg) ladasten administration versus placebo has been studied in patients with neurasthenia diagnosis.
Report a problemFND-2228815302
03HumanNon-randomized trialOther
In patients with neurasthenia, self-rated ladasten effects correlated with some baseline psychopathological and psychophysiological parameters, main effects, and overall treatment efficacy.
In plain wordsIn patients with neurasthenia, self-rated ladasten effects were linked to some baseline measures, main drug effects, and overall treatment efficacy.
Peptide
Bromantane
Outcome
Direction not reportedCorrelates of self-rated effects
Study
n: not reported in source
Outcome group
Patient-reported outcomes · Mental health and mood
Studied dose
15 mg · single doseAs given in this study (human).
Source sentences
Summary
Correlations of the self-estimations and some psychopathological and psychophysiological parameters before treatment, main drug effects, and overall course treatment effectiveness are revealed
1 context sentence(design, population, supporting numbers)
Summary · context
Self-evaluation of the effect of single-dose (15 mg) ladasten administration versus placebo has been studied in patients with neurasthenia diagnosis.
Report a problemFND-2228815303

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.